Bausch & Lomb Ophthalmic ZyLET Is “Approvable” At FDA

The company expects to launch the anti-inflammatory/antibiotic agent Zylet by year-end. Bausch & Lomb acquired rights to the loteprednol ophthalmic business from Pharmos.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet